GW Pharmaceuticals ROA 2024

GW Pharmaceuticals Aktienanalyse

What does GW Pharmaceuticals do?

GW Pharmaceuticals PLC is a British company that has been involved in the development and manufacturing of prescription medications based on cannabis since 1998. The company is a global leader in the research of medical cannabis and is headquartered in Cambridge. The history of GW Pharmaceuticals traces back to the founding of the company by Dr. Geoffrey Guy, who focused on the medical use of cannabis. In its early years, the company focused on developing medicinal cannabis strains with high levels of cannabinoids, such as THC or CBD. A pivotal moment for the company was the approval of Sativex in 2010, a medication for the treatment of spastic symptoms in multiple sclerosis. This was the first cannabis-based medication to be approved by a regulatory authority. Since then, GW Pharmaceuticals has expanded its portfolio of products and is involved in various areas, including the treatment of epilepsy, autism, pain, insomnia, and cancer. The company has several medications in late-stage clinical development and plans to bring more medications to the market. GW Pharmaceuticals' business model is based on researching, manufacturing, and selling medical cannabis. The company is an innovative pioneer in this field and works closely with health authorities and medical professionals to ensure the safety and efficacy of its products. GW Pharmaceuticals operates in several sectors, including the development of medical cannabis, the manufacturing of medications, and collaboration with health authorities and medical professionals. The company strives to develop high-quality and safe products that improve patients' quality of life. One of GW Pharmaceuticals' key products is Epidiolex, a medication for the treatment of severe forms of epilepsy in children. The medication contains CBD, one of the compounds found in medical cannabis, and has been approved by the U.S. Food and Drug Administration (FDA). Another important product of GW Pharmaceuticals is Sativex, a spray for the treatment of spastic symptoms in multiple sclerosis. The medication contains a combination of THC and CBD and is approved in several countries. GW Pharmaceuticals also has products in the pipeline targeting the treatment of autism, pain, insomnia, and cancer. The company is committed to advancing the use of medical cannabis and its compounds in medical practice and contributing to the improvement of health. Overall, GW Pharmaceuticals has made a significant contribution to the research and development of medical cannabis and has established itself as a leader in this field. The company is dedicated to developing high-quality medications that improve patients' lives and contribute to improving health. GW Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding GW Pharmaceuticals's Return on Assets (ROA)

GW Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing GW Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider GW Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in GW Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about GW Pharmaceuticals Stock

What is the Return on Assets (ROA) of GW Pharmaceuticals this year?

The Return on Assets (ROA) of GW Pharmaceuticals is 0 undefined this year.

What was the ROA of GW Pharmaceuticals compared to the previous year?

The ROA of GW Pharmaceuticals has increased by 0% compared to the previous year.

What consequences do high ROA have for investors of GW Pharmaceuticals?

A high ROA is advantageous for investors of GW Pharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in GW Pharmaceuticals?

A low ROA can be unfavorable for investors of GW Pharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of GW Pharmaceuticals affect the company?

An increase in ROA of GW Pharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of GW Pharmaceuticals impact the company?

A reduction in the ROA of GW Pharmaceuticals can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of GW Pharmaceuticals?

Some factors that can influence the ROA of GW Pharmaceuticals include revenue, operating costs, asset structure, and industry average.

Why is the ROA of GW Pharmaceuticals important for investors?

The ROA of GW Pharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can GW Pharmaceuticals take to improve ROA?

To improve ROA, GW Pharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does GW Pharmaceuticals pay?

Over the past 12 months, GW Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, GW Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of GW Pharmaceuticals?

The current dividend yield of GW Pharmaceuticals is .

When does GW Pharmaceuticals pay dividends?

GW Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of GW Pharmaceuticals?

GW Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of GW Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is GW Pharmaceuticals located?

GW Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von GW Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GW Pharmaceuticals from 6/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/9/2024.

When did GW Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/9/2024.

What was the dividend of GW Pharmaceuticals in the year 2023?

In the year 2023, GW Pharmaceuticals distributed 0 USD as dividends.

In which currency does GW Pharmaceuticals pay out the dividend?

The dividends of GW Pharmaceuticals are distributed in USD.